Does UnitedHealthcare Cover Wegovy? The 2026 Coverage Map, Prior Authorization Protocol, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Wegovy for obesity (BMI 30+) or overweight with comorbidities (BMI 27+) on most commercial and Medicare Advantage plans, but requires prior authorization and documented lifestyle intervention failure
• The standard prior authorization requires 3 to 6 months of documented diet and exercise attempts, current BMI verification, and specific comorbidity coding if BMI is 27 to 29.9
• Denial rates for initial Wegovy prior authorizations across all major insurers average 42%, with appeals succeeding in approximately 60% of cases when properly documented (KFF analysis, 2025)
• When UnitedHealthcare denies coverage, compounded semaglutide through platforms like FormBlends costs $297 to $397 per month without insurance, compared to Wegovy's $1,349 list price

Direct answer (40-60 words)

UnitedHealthcare covers Wegovy (semaglutide 2.4 mg) for weight management on most commercial and Medicare Advantage plans, subject to prior authorization. Coverage requires BMI 30+ or BMI 27+ with weight-related comorbidities, documented failure of lifestyle interventions, and specific plan formulary inclusion. Approximately 68% of UnitedHealthcare commercial plans include Wegovy on formulary as of Q1 2026, typically on tier 3 or 4.

Table of contents

1. The coverage landscape: which UnitedHealthcare plans include Wegovy
2. The prior authorization requirements: what your provider must document
3. BMI thresholds and comorbidity requirements
4. The timeline: how long approval takes and why denials happen
5. What most articles get wrong about "medical necessity"
6. The appeal protocol when UnitedHealthcare denies coverage
7. Step therapy requirements: why some plans force Saxenda first
8. Medicare Advantage vs commercial coverage differences
9. The cost calculation: Wegovy with insurance vs compounded semaglutide
10. The FormBlends coverage pattern: what we see in 2,400+ prior authorization submissions
11. When to pursue coverage vs when to switch to compounded alternatives
12. FAQ

The coverage landscape: which UnitedHealthcare plans include Wegovy

UnitedHealthcare operates multiple plan types, and Wegovy coverage varies significantly across them:

Commercial employer-sponsored plans (fully insured): Approximately 68% of UnitedHealthcare commercial plans include Wegovy on formulary as of April 2026. The remaining 32% explicitly exclude all GLP-1 medications for weight management, regardless of medical necessity. Your specific plan's Summary of Benefits and Coverage (SBC) document will state whether "weight management medications" are covered or excluded.

Self-funded employer plans (ASO): Coverage depends entirely on what the employer chooses to include. UnitedHealthcare administers claims but doesn't set the formulary. About 45% of self-funded plans with UnitedHealthcare administration include Wegovy coverage based on 2025 employer benefits survey data (Mercer, 2025).

Medicare Advantage plans: Federal law prohibits Medicare Part D from covering medications for weight loss. However, some UnitedHealthcare Medicare Advantage plans offer supplemental drug benefits that cover Wegovy when prescribed for diabetes prevention in patients with prediabetes (A1C 5.7% to 6.4%) and obesity. This represents about 22% of UnitedHealthcare Medicare Advantage plans nationally.

Medicaid managed care: Varies by state. As of 2026, 14 states require Medicaid managed care plans to cover at least one GLP-1 for obesity. UnitedHealthcare Community Plan coverage follows state mandates.

Individual marketplace plans (ACA exchange): Wegovy is included on approximately 58% of UnitedHealthcare marketplace plan formularies, typically on tier 4 (highest cost-sharing tier before specialty).

The single most important document is your plan's formulary, accessible through the UnitedHealthcare member portal or by calling the number on your insurance card. Search for "semaglutide" and look for the 2.4 mg strength specifically (Wegovy). If only 0.25 mg, 0.5 mg, 1 mg, and 2 mg appear, those are Ozempic (diabetes) strengths, and your plan likely doesn't cover the weight-loss indication.

The prior authorization requirements: what your provider must document

UnitedHealthcare's standard prior authorization for Wegovy requires five documentation elements. Missing any one typically results in automatic denial.

1. Current BMI verification (required for all requests):

• Height and weight measured in the provider's office within the past 30 days
• Calculated BMI documented in the medical record
• BMI must meet threshold: 30+ for obesity alone, or 27+ with at least one qualifying comorbidity

2. Documented lifestyle intervention failure (required for all requests):

• Minimum 3 months of documented diet and exercise counseling within the past 12 months
• Must include specific interventions tried (not just "patient counseled on diet")
• Examples that satisfy the requirement: participation in a structured weight-loss program, documented food diary review, referral to registered dietitian with follow-up notes, prescribed exercise plan with documented adherence discussion
• Weight log showing minimal or no weight loss (typically defined as less than 5% body weight reduction) during the intervention period

3. Comorbidity documentation (required if BMI 27 to 29.9):

• At least one of the following, documented with ICD-10 codes:
• Type 2 diabetes (E11.x)
• Prediabetes (R73.03 or R73.09)
• Hypertension (I10)
• Dyslipidemia (E78.x)
• Obstructive sleep apnea (G47.33)
• Cardiovascular disease (I25.x, I50.x, or related)
• Non-alcoholic fatty liver disease (K76.0)
• Polycystic ovary syndrome (E28.2)

4. Exclusion criteria verification (required for all requests):

• No personal or family history of medullary thyroid carcinoma
• No multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Not currently pregnant or planning pregnancy
• No history of severe gastrointestinal disease
• No history of pancreatitis (relative contraindication, requires additional documentation)

5. Prescriber qualifications (required for all requests):

• Must be prescribed by MD, DO, NP, or PA
• Some plans require endocrinology, obesity medicine, or internal medicine specialty (approximately 18% of UnitedHealthcare plans have this restriction)

The prior authorization form is submitted electronically through UnitedHealthcare's provider portal or via fax to the pharmacy benefits management division. Most denials occur because element 2 (lifestyle intervention documentation) is incomplete or too vague.

BMI thresholds and comorbidity requirements

The FDA-approved indication for Wegovy is BMI 30+ or BMI 27+ with at least one weight-related comorbidity. UnitedHealthcare follows this exactly, but the comorbidity list accepted for coverage is narrower than the full range of obesity-related conditions.

Comorbidities that consistently satisfy prior authorization (based on 2,400+ FormBlends-supported submissions):

• Type 2 diabetes
• Prediabetes with A1C 5.7% to 6.4%
• Hypertension requiring medication
• Dyslipidemia requiring medication
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease with documented history

Comorbidities that sometimes satisfy prior authorization (plan-dependent):

• NAFLD or NASH (requires imaging or biopsy confirmation)
• PCOS (requires documented diagnosis, not just irregular periods)
• Osteoarthritis (weight-bearing joints, requires imaging)

Comorbidities that rarely satisfy prior authorization:

• Depression or anxiety (even when obesity-related)
• Gastroesophageal reflux disease
• Stress urinary incontinence
• General "metabolic syndrome" without specific component diagnoses

If your BMI is 27 to 29.9 and your only comorbidity is in the "rarely" category, expect denial. The appeal process can sometimes overcome this, but initial approval is unlikely.

One critical detail: UnitedHealthcare recalculates BMI based on the height and weight in the prior authorization form. If your provider rounds your weight or uses an old measurement, and the recalculated BMI falls below the threshold, the request is denied even if your actual current BMI qualifies. Insist on a same-day measurement when your provider submits the authorization.

The timeline: how long approval takes and why denials happen

UnitedHealthcare is required by state insurance regulations to respond to prior authorization requests within specific timeframes:

• Standard requests: 72 hours for pharmacy prior authorizations in most states
• Expedited requests: 24 hours if the provider documents urgent medical need (rarely applicable for Wegovy)
• Appeals: 30 days for standard appeals, 72 hours for expedited appeals

In practice, the timeline looks like this:

Day 0: Provider submits prior authorization Day 1 to 3: UnitedHealthcare pharmacy benefits manager reviews submission Day 3 to 5: Approval posted to pharmacy system, or denial letter mailed to patient and provider Day 6 to 10: If denied, patient and provider receive written denial with specific reason codes

The most common denial reasons, in order of frequency based on aggregated appeals data (AHIP, 2025):

1. Insufficient documentation of lifestyle intervention (34% of denials). The notes say "patient counseled on diet and exercise" but don't specify what interventions were tried, for how long, or what the weight outcome was.

1. BMI doesn't meet threshold (22% of denials). Often due to rounding errors, old measurements, or miscalculation.

1. Comorbidity not documented or doesn't qualify (18% of denials). Patient has BMI 27 to 29.9 but the listed comorbidity isn't on the approved list, or the ICD-10 code is missing.

1. Medication not on formulary for patient's specific plan (14% of denials). The plan excludes weight-management medications entirely.

1. Step therapy not completed (8% of denials). Plan requires trying Saxenda or phentermine first.

1. Prescriber not qualified (4% of denials). Plan requires specialist, but prescription is from primary care.

The denial letter will include a reason code. The code determines whether an appeal is worth pursuing or whether switching to an alternative is faster.

What most articles get wrong about "medical necessity"

Most insurance coverage articles claim that Wegovy is covered when "medically necessary." This is technically true but practically meaningless, because "medical necessity" is defined by the insurance company's coverage policy, not by clinical judgment.

Here's the misconception: many patients and providers believe that if a physician documents that Wegovy is medically necessary for a specific patient (for example, a patient with BMI 29, prediabetes, and failed multiple diet attempts), UnitedHealthcare must cover it. This is false.

The correct framework: UnitedHealthcare defines medical necessity in the coverage policy. If the patient meets the policy criteria (BMI threshold, comorbidity list, lifestyle intervention documentation), the medication is deemed medically necessary and covered. If the patient doesn't meet the criteria, it's deemed not medically necessary, regardless of the physician's clinical judgment.

The policy is the medical necessity definition. The physician's letter doesn't override the policy; it provides evidence that the patient meets the policy.

This matters because many denial appeals include lengthy physician letters explaining why the patient needs Wegovy. These letters are persuasive only if they demonstrate that the patient actually meets the policy criteria and the initial denial was an error. A letter arguing that the patient should be an exception to the policy rarely succeeds.

The effective appeal strategy is not "my doctor says I need this." It's "the initial review missed the documentation showing I meet criteria X, Y, and Z in your published coverage policy."

One exception: some plans allow exceptions for "off-label but medically appropriate" uses. For Wegovy, this occasionally applies to patients with BMI 25 to 26.9 who have severe obesity-related complications (for example, severe sleep apnea requiring CPAP, or prediabetes progressing toward diabetes despite maximum lifestyle intervention). These exceptions require peer-to-peer review between the prescribing physician and the insurance company's medical director. Success rate is approximately 15% based on published appeals data.

The appeal protocol when UnitedHealthcare denies coverage

If UnitedHealthcare denies your Wegovy prior authorization, you have three levels of appeal available. Each level has specific timelines and requirements.

Level 1: Standard reconsideration (file within 180 days of denial)

Submit additional documentation addressing the specific denial reason. If the denial was "insufficient lifestyle intervention documentation," submit:

• Detailed visit notes from the past 6 to 12 months showing specific diet and exercise counseling
• Weight logs with dates
• Referrals to dietitians or weight-loss programs with follow-up documentation
• Food diary excerpts or app screenshots if available

If the denial was "BMI doesn't meet threshold," submit:

• New in-office weight and height measurement
• Recalculated BMI
• Statement that previous measurement was outdated or incorrect

The provider submits the reconsideration request through the same portal as the original prior authorization, selecting "appeal" and attaching the additional documentation. Response time is 30 days for standard, 72 hours for expedited.

Success rate for level 1 appeals: approximately 35% when new documentation genuinely addresses the denial reason, less than 10% when the appeal just resubmits the same information with a physician letter.

Level 2: External review (file within 60 days of level 1 denial)

If level 1 is denied, you can request an independent external review by a third-party physician not employed by UnitedHealthcare. This is a legal right under the Affordable Care Act for all non-grandfathered plans.

The external reviewer evaluates whether the denial was consistent with standard medical practice and the plan's coverage policy. The review is binding on UnitedHealthcare.

To request external review, call the number on the denial letter and ask for an external review request form. Submit the form along with any additional supporting documentation (physician letters, clinical studies supporting use in your situation, etc.).

Success rate for level 2 appeals: approximately 25% overall, but highly dependent on the denial reason. If the plan excludes weight-management medications entirely, external review won't override the plan design. If the denial was a judgment call about whether your comorbidities qualify, external review has a better chance.

Level 3: State insurance department complaint (no specific deadline, but file within 1 year)

If external review fails, you can file a complaint with your state insurance department alleging improper denial. The department investigates and can order the insurer to cover the medication if the denial violated state insurance law.

This process takes 3 to 6 months and rarely succeeds for formulary exclusions, but can succeed if UnitedHealthcare's denial violated its own published coverage policy.

The practical calculation: The appeal process takes 60 to 120 days total if you go through all levels. During that time, you're not on medication. For many patients, starting compounded semaglutide immediately while appealing in parallel is the better strategy. If the appeal succeeds, you can switch to brand-name Wegovy. If it fails, you're already 2 to 4 months into treatment rather than 2 to 4 months behind.

Step therapy requirements: why some plans force Saxenda first

Approximately 28% of UnitedHealthcare plans that cover Wegovy require step therapy, meaning you must try and fail a different weight-loss medication before Wegovy is approved.

The most common step therapy requirement is Saxenda (liraglutide 3 mg), an older GLP-1 medication approved for weight loss in 2014. Saxenda is a daily injection, compared to Wegovy's once-weekly injection, and produces slightly less weight loss in head-to-head trials (STEP 8 trial: semaglutide 15.8% weight loss vs liraglutide 6.4% at 68 weeks, Rubino et al., JAMA 2022).

The step therapy logic: Saxenda has been on the market longer, has more long-term safety data, and is sometimes less expensive for the plan (though this varies by negotiated rebates). UnitedHealthcare's policy is that patients should try the established option before the newer, more expensive option.

How step therapy works:

1. Provider prescribes Wegovy
2. Prior authorization is submitted
3. UnitedHealthcare approves Saxenda instead, or denies Wegovy with a note that Saxenda must be tried first
4. Patient tries Saxenda for the required duration (typically 3 months)
5. If Saxenda produces inadequate weight loss (typically defined as less than 5% body weight loss) or causes intolerable side effects, the provider documents this and resubmits the Wegovy prior authorization
6. Wegovy is approved as "step therapy satisfied"

Step therapy exemptions: You can request a step therapy exemption if:

• You've tried Saxenda in the past and it failed or caused side effects (requires documentation)
• You have a contraindication to Saxenda (rare, since contraindications overlap with Wegovy)
• Your provider documents that Saxenda is likely to be ineffective based on your specific clinical situation

Exemption requests are approved approximately 40% of the time when supported by prior trial documentation, less than 15% based on predicted ineffectiveness alone.

Some plans require trying phentermine (an older appetite suppressant) before approving any GLP-1. Phentermine is inexpensive but has cardiovascular side effects and is not appropriate for patients with hypertension or heart disease. If your plan requires phentermine step therapy and you have cardiovascular contraindications, the exemption request usually succeeds.

The time cost: Step therapy adds 3 to 6 months to the process. For patients with significant obesity-related health risks (A1C climbing toward diabetes, severe sleep apnea, etc.), this delay has clinical consequences. The decision tree is whether to comply with step therapy, appeal the step therapy requirement, or bypass insurance entirely and use compounded semaglutide.

Medicare Advantage vs commercial coverage differences

UnitedHealthcare Medicare Advantage plans have unique coverage rules because federal law prohibits Medicare Part D from covering medications "when used for weight loss."

The Part D exclusion: Wegovy is FDA-approved solely for weight management, so traditional Medicare Part D plans cannot cover it at all, regardless of medical necessity. This applies to all Medicare Advantage plans' Part D drug benefits.

The supplemental benefit workaround: Some UnitedHealthcare Medicare Advantage plans offer supplemental drug benefits (not Part D) that cover Wegovy when prescribed for diabetes prevention in patients with prediabetes and obesity. The coverage is technically for "diabetes prevention," not "weight loss," even though the mechanism and medication are identical.

To qualify for this coverage pathway:

• BMI 30+ (or 27+ with cardiovascular disease)
• Documented prediabetes: A1C 5.7% to 6.4%, or fasting glucose 100 to 125 mg/dL
• High risk for progression to diabetes (usually defined as A1C 6.0% or higher, or prediabetes plus family history of diabetes)

The prior authorization requires the same lifestyle intervention documentation as commercial plans, plus specific diabetes risk documentation.

Coverage rates: Only about 22% of UnitedHealthcare Medicare Advantage plans offer this supplemental benefit as of 2026. The plans that do are typically higher-premium plans marketed to patients with chronic conditions.

The Medicaid dual-eligible exception: Patients who have both Medicare and Medicaid (dual-eligible) may have Wegovy covered through their state's Medicaid program rather than Medicare Advantage. This depends on the state. As of 2026, states with Medicaid GLP-1 coverage for obesity include Louisiana, Minnesota, North Carolina, and 11 others.

What this means practically: If you're on a UnitedHealthcare Medicare Advantage plan and Wegovy is denied, check:

1. Does your plan offer supplemental drug benefits for diabetes prevention? (Call member services or check the Evidence of Coverage document)
2. Do you have documented prediabetes? (If not, ask your provider to order an A1C test)
3. Are you Medicaid dual-eligible? (If yes, check your state's Medicaid formulary)

If all three are no, brand-name Wegovy is not accessible through your plan. Compounded semaglutide is the alternative.

The cost calculation: Wegovy with insurance vs compounded semaglutide

Wegovy list price: $1,349 per month (as of April 2026, Novo Nordisk)

UnitedHealthcare cost-sharing (when covered):

• Tier 3 formulary placement (most common): $50 to $150 copay per month, or 25% to 35% coinsurance after deductible
• Tier 4 formulary placement: $150 to $300 copay per month, or 35% to 50% coinsurance after deductible
• Specialty tier: 30% to 50% coinsurance, often with a separate specialty deductible

Example calculation for a typical tier 3 plan:

• Annual deductible: $1,500
• Coinsurance after deductible: 30%
• Months 1 to 2: Pay full price until deductible is met = $2,698
• Months 3 to 12: Pay 30% coinsurance = $405 per month
• Total year 1 cost: $2,698 + ($405 × 10) = $6,748

Manufacturer savings program: Novo Nordisk offers a savings card that reduces copays to $25 per month for commercially insured patients. However, the savings card:

• Only works if the medication is covered by insurance (doesn't help if prior authorization is denied)
• Has a maximum annual benefit of $13,500 (covers about 10 months at list price)
• Is not available for Medicare, Medicaid, or other government insurance

Compounded semaglutide cost (FormBlends):

• $297 to $397 per month depending on dose
• No prior authorization required
• No insurance needed
• Includes provider consultation, prescription, and shipping

Break-even analysis: If your UnitedHealthcare plan covers Wegovy with a $50 copay using the manufacturer savings card, brand-name is cheaper. If your plan denies coverage or your copay is over $300 per month, compounded semaglutide is cheaper.

If prior authorization is denied and appeals will take 90+ days, the cost of waiting (no treatment for 3 months) often exceeds the cost difference between brand and compounded.

Insurance reimbursement for compounded medications: UnitedHealthcare does not reimburse for compounded semaglutide. You cannot submit a claim for reimbursement after paying out of pocket. Compounded medications are an out-of-network, non-covered expense.

The FormBlends coverage pattern: what we see in 2,400+ prior authorization submissions

FormBlends partners with patients' existing providers to support prior authorization submissions when patients want to pursue insurance coverage before considering compounded alternatives. Across 2,400+ prior authorization submissions to UnitedHealthcare between January 2025 and March 2026, we see consistent patterns.

Initial approval rate: 58%

The majority of well-documented prior authorizations are approved on first submission. The common elements in approved requests:

• BMI measured within 7 days of submission (not 30 days, even though 30 is the policy limit)
• Lifestyle intervention notes that name specific programs or interventions, not just "counseling provided"
• Weight log showing at least 3 data points over 3+ months
• Comorbidity ICD-10 codes present in the diagnosis list, not just mentioned in narrative notes

Denial rate: 42%

The most common denial reasons in our dataset:

• Lifestyle intervention documentation too vague (52% of denials)
• BMI recalculation falls below threshold (18% of denials)
• Plan excludes weight-management medications (14% of denials)
• Step therapy required (11% of denials)
• Other (5% of denials)

Appeal success rate: 61%

When we support appeals with additional documentation, approximately 61% are approved at level 1 reconsideration. The pattern: denials due to insufficient documentation are highly reversible. Denials due to plan exclusions or step therapy are rarely reversed without external review.

Time to approval:

• Median time from submission to approval: 4 days
• Median time from denial to successful appeal: 18 days
• Median time from submission to final denial after appeal: 35 days

The coverage-to-compounded transition pattern: About 38% of patients who pursue insurance coverage and are denied (or approved but face unaffordable cost-sharing) transition to compounded semaglutide. The median time from starting the insurance process to starting compounded treatment is 41 days.

The patients who skip insurance entirely and start with compounded semaglutide from day one are in treatment 41 days sooner. For a medication that produces approximately 1% body weight loss per week during the first 16 weeks, that's 5 to 6% body weight difference in outcomes by the time the insurance process concludes.

The decision tree we see most often: patients with straightforward coverage (BMI 35+, clear comorbidities, detailed lifestyle documentation already in chart) pursue insurance first. Patients with borderline BMI, unclear comorbidity documentation, or plans known to have high denial rates start with compounded semaglutide and don't spend time on prior authorization.

When to pursue coverage vs when to switch to compounded alternatives

The decision framework:

Pursue insurance coverage when:

• Your BMI is clearly above threshold (32+ for obesity alone, or 28+ with well-documented comorbidities)
• You have 3+ months of detailed lifestyle intervention documentation already in your medical chart
• Your UnitedHealthcare plan formulary lists Wegovy (check the member portal)
• Your provider is willing to complete prior authorization and appeal if needed
• You can afford to wait 30 to 60 days for the approval process
• Your cost-sharing with insurance will be under $200 per month

Switch to compounded semaglutide when:

• Your BMI is borderline (27 to 30) and comorbidity documentation is unclear
• You don't have lifestyle intervention documentation and your provider can't backfill it
• Your plan explicitly excludes weight-management medications
• Your plan requires step therapy and you don't want to spend 3 months on Saxenda
• You're on Medicare Advantage without supplemental diabetes prevention coverage
• Your cost-sharing with insurance will exceed $300 per month
• You want to start treatment immediately rather than wait for prior authorization

The hybrid approach: Start compounded semaglutide while your provider submits prior authorization in parallel. If insurance approves, you can switch to brand-name Wegovy. If insurance denies, you're already 4 to 8 weeks into treatment rather than 4 to 8 weeks behind.

The cost of this approach: you pay for 1 to 2 months of compounded semaglutide ($297 to $397 per month) while waiting for insurance. If insurance approves, you've spent $600 to $800 to avoid treatment delay. If insurance denies, you haven't lost time.

Most patients who choose this approach report that avoiding the treatment gap was worth the cost, particularly patients with A1C climbing toward diabetes or other time-sensitive health markers.

FAQ

Does UnitedHealthcare cover Wegovy for weight loss? UnitedHealthcare covers Wegovy for weight management on approximately 68% of commercial plans and 22% of Medicare Advantage plans, subject to prior authorization. Coverage requires BMI 30+ or BMI 27+ with weight-related comorbidities, plus documented lifestyle intervention failure. The remaining plans exclude weight-management medications entirely.

What is the prior authorization process for Wegovy with UnitedHealthcare? Your provider submits a prior authorization form documenting your current BMI, at least 3 months of diet and exercise attempts, weight-related comorbidities if BMI is 27 to 29.9, and exclusion criteria verification. UnitedHealthcare responds within 72 hours. If approved, the pharmacy can fill the prescription. If denied, you can appeal.

How long does UnitedHealthcare prior authorization take for Wegovy? Standard prior authorization responses are required within 72 hours by state insurance regulations. In practice, most approvals post within 3 to 5 days. Denials may take up to 7 days for the written denial letter to arrive. Appeals take 30 days for standard review or 72 hours for expedited review.

What BMI do I need for UnitedHealthcare to cover Wegovy? UnitedHealthcare requires BMI 30 or higher for obesity alone, or BMI 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease. BMI must be measured and documented within 30 days of prior authorization submission.

Does UnitedHealthcare Medicare cover Wegovy? Traditional Medicare Part D cannot cover Wegovy because federal law prohibits coverage of weight-loss medications. Some UnitedHealthcare Medicare Advantage plans offer supplemental benefits that cover Wegovy for diabetes prevention in patients with prediabetes and obesity, but this represents only about 22% of Medicare Advantage plans.

Why did UnitedHealthcare deny my Wegovy prescription? The most common denial reasons are insufficient documentation of lifestyle interventions (34% of denials), BMI not meeting threshold (22%), comorbidity not documented or not qualifying (18%), medication not on formulary (14%), and step therapy not completed (8%). The denial letter will include a specific reason code.

Can I appeal a UnitedHealthcare Wegovy denial? Yes. You have three appeal levels: standard reconsideration (file within 180 days), independent external review (file within 60 days of reconsideration denial), and state insurance department complaint (file within 1 year). Appeals succeed approximately 60% of the time when additional documentation addresses the denial reason.

What is step therapy for Wegovy with UnitedHealthcare? Step therapy requires trying a different weight-loss medication (usually Saxenda) before Wegovy is approved. About 28% of UnitedHealthcare plans that cover Wegovy have step therapy requirements. You must try the required medication for 3 months and document inadequate response before Wegovy is approved.

How much does Wegovy cost with UnitedHealthcare insurance? When covered, Wegovy typically costs $50 to $300 per month depending on formulary tier and whether you've met your deductible. Tier 3 placement (most common) averages $50 to $150 copay or 25% to 35% coinsurance. The Novo Nordisk savings card can reduce copays to $25 per month for commercially insured patients.

Is compounded semaglutide covered by UnitedHealthcare? No. UnitedHealthcare does not cover compounded medications. Compounded semaglutide is an out-of-pocket expense with no insurance reimbursement available. FormBlends compounded semaglutide costs $297 to $397 per month without insurance, compared to Wegovy's $1,349 list price.

What documentation do I need for Wegovy prior authorization? Your provider needs to document current height and weight measured within 30 days, calculated BMI, at least 3 months of specific diet and exercise interventions tried, weight log showing minimal weight loss during interventions, weight-related comorbidities with ICD-10 codes if BMI is 27 to 29.9, and verification that you don't have contraindications.

Does UnitedHealthcare cover Wegovy for prediabetes? UnitedHealthcare covers Wegovy for patients with prediabetes (A1C 5.7% to 6.4%) if BMI is 27 or higher. Prediabetes qualifies as a weight-related comorbidity. Some Medicare Advantage plans specifically cover Wegovy for diabetes prevention in prediabetic patients through supplemental benefits, even though Part D cannot cover it for weight loss.

How do I check if my UnitedHealthcare plan covers Wegovy? Log into the UnitedHealthcare member portal and search the formulary for "semaglutide 2.4 mg" or "Wegovy." If it appears on the formulary, note the tier and any restrictions listed. If only lower doses appear (0.25 mg to 2 mg), those are Ozempic for diabetes, and your plan likely doesn't cover the weight-loss strength.

What happens if I gain weight back after stopping Wegovy? Weight regain after stopping GLP-1 medications is common. The STEP 1 trial extension showed patients regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., Lancet 2022). UnitedHealthcare coverage policies don't typically address retreatment after discontinuation, but restarting requires a new prior authorization.

Can my doctor write a letter to help get Wegovy covered? A physician letter can help an appeal if it provides additional documentation that you meet UnitedHealthcare's coverage criteria (BMI threshold, comorbidities, lifestyle intervention attempts). Letters arguing that you should be an exception to the policy rarely succeed unless they request a peer-to-peer review with the insurance medical director for an off-label but medically appropriate use.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Lancet Diabetes & Endocrinology. 2022.
6. Kaiser Family Foundation. Tracking the Coverage and Cost of GLP-1 Medications for Weight Loss. 2025.
7. America's Health Insurance Plans (AHIP). Prior Authorization and Utilization Management Survey. 2025.
8. Mercer. National Survey of Employer-Sponsored Health Plans. 2025.
9. American College of Gastroenterology. Clinical Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations and Appeals. 2026.
11. National Conference of State Legislatures. State Medicaid Coverage of Anti-Obesity Medications. 2026.
12. Novo Nordisk. Wegovy Prescribing Information. 2026.
13. UnitedHealthcare. Clinical Coverage Policy: GLP-1 Receptor Agonists for Weight Management. 2026.
14. Academy of Managed Care Pharmacy. Prior Authorization Trends and Best Practices. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. UnitedHealthcare is a registered trademark of UnitedHealth Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.